Zivo Bioscience Inc SEC Filings

Zivo Bioscience (ZIVO) reported an insider purchase. Director and 10% owner Laith L. Yaldoo acquired 1,659 shares of common stock on 10/10/2025 at $12.05 per share, held indirectly through HEP Investments LLC. Following the trade, beneficial ownership was 575,095 shares, reported as indirect.

Christopher D. Maggiore, a director and reported >10% owner of Zivo Bioscience, Inc. (ZIVO), purchased 23,682 shares of the companys common stock on 10/08/2025 at a price of $12.01 per share. After this transaction the filing reports aggregate beneficial ownership of 517,526 shares, which corrects a prior overstatement caused by an administrative error that had overstated ownership by 13,156 shares. The transaction is reported on a Form 4 and was signed by the reporting person on 10/09/2025. The filing shows the acquisition coded as P and lists the ownership form as Direct.

Zivo Bioscience (ZIVO) reported an insider equity award. On 10/02/2025, a reporting person who is a Director and 10% Owner received 926 nonstatutory stock options to buy common stock at an exercise price of $12.03 per share, expiring on 10/02/2035. The filing notes the option grant was issued under the 2024 Equity Incentive Plan for Non-Employee Directors in lieu of retainer fees totaling $9,452.05. Ownership of these derivative securities is listed as Direct (D).

Zivo Bioscience, Inc. (ZIVO) director and 10% owner Christopher D. Maggiore was granted 1,075 nonstatutory stock options on 10/02/2025 under the 2024 Equity Incentive Plan for Non-Employee Directors in lieu of retainer fees of $10,964.38. The options have an exercise price of $12.03, are exercisable immediately on 10/02/2025, and expire on 10/02/2035. The filing shows the underlying common stock amount as 1,075 shares and reports the transaction on a Form 4 signed 10/06/2025. This is a routine director compensation award recorded as equity rather than cash.

Zivo Bioscience, Inc. (ZIVO) director Alison Cornell received a grant of 1,223 nonstatutory stock options on 10/02/2025 under the 2024 Equity Incentive Plan for Non-Employee Directors in lieu of retainer fees totaling $12,476.71. The options have an exercise price of $12.03, are exercisable immediately on 10/02/2025, and expire on 10/02/2035

This transaction increases the reporting person’s direct beneficial ownership by 1,223 underlying shares. The filing is a routine director compensation disclosure showing equity issued instead of cash fees to align compensation with shareholder interests.

Laith Yaldoo, a director and 10% owner of Zivo Bioscience, Inc. (ZIVO), reported a purchase of 15,322 shares of the company's common stock on 09/30/2025 at a price of $15.99 per share. After the transaction, the filing shows beneficial ownership of 573,436 shares held indirectly through HEP Investments LLC. The Form 4 was signed on 10/02/2025.

This report documents an insider acquisition, increasing the reporting person's indirect stake via an investment vehicle. The filing does not disclose any derivative transactions or additional context for the purchase beyond the amounts, price, and ownership form.